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Summary 
The importance of cytotoxic T  lymphocytes (CTLs) in the immunosurveillance of Epstein- 
Barr virus (EBV)-infected B cells is firmly established,  and the viral antigens  of CTL recognition in 
latent infection are well defined. The epitopes targeted by CTLs during primary infection have 
not been identified, however, and there is only limited information about T  cell receptor (TCR) 
selection.  In  the  present report,  we  have  monitored the  development of memory TCR-[3 
clonotypes selected in response to natural EBV infection in a longitudinal study of an HLA- 
B8 +  individual  with  acute  infectious mononucleosis  (IM).  By stimulating  peripheral blood 
lymphocytes with HLA-B8  + EBV-transformed B lymphoblastoid cells, the primary virus-spe- 
cific CTL response was shown to include specificities for two HLA-B8-restricted antigenic de- 
terminants,  FLRGRAYGL and QAKWRLQTL, which are encoded within the latent EBV 
nuclear antigen EBNA-3. TC1L-[3  sequence analysis of CTL clones specific for each epitope 
showed polyclonal TCR-[3 repertoire selection, with structural restrictions on recognition that 
indicated antigen-driven selection. Furthermore, longitudinal repertoire analysis revealed long- 
term preservation of a multiclonal effector response throughout convalescence, with the re- 
emergence of distinct memory T cell clonotypes sharing similar structural restrictions. Tracking 
the progression of specific TC1L-[3 clonotypes and antigen-specific TCR-VJ3 family gene ex- 
pression in the peripheral repertoire ex vivo using semiquantitative PCR strongly suggested 
that selective TC1L-[3 expansions were present at the clonotype level, but not at the TC1L-V[3 
family level. Overall, in this first analysis of antigen-specific TCR development in IM, a picture 
of polyclonal TC1L stimulation is apparent. This diversity may be especially important in the 
establishment of an effective CTL control during acute EBV infection and in recovery from 
disease. 
E 
BV is a gammaherpesvirus of humans that has potent B 
cell growth-transforming activity (1, 2). The virus per- 
sists as a latent infection of  B cells under the control of class 
I-restricted CD8 + CTLs that recognize the latent viral an- 
tigens, which include the EBV nuclear antigens  (EBNAs) 1 
2-6 and the latent membrane proteins (3).  Primary infec- 
tion generally occurs asymptomatically in early childhood; 
however, if infection is delayed until adolescence or adult- 
hood,  it  can lead  to  the  self-limiting lymphoproliferative 
disease acute infectious mononucleosis (IM) (4). A vigorous 
cellular immune reaction, dominated by activated and pro- 
liferating CD8 + CTLs, is mounted during acute IM in re- 
IAbbreviauons used in this paper: EBNA, EBV nuclear antigen; IM, infec- 
txous mononucleosis;  LCL, lymphoblastoid  cell  hne. 
sponse to virus-infected B cells in the peripheral blood and 
lymphoid  tissues  (5).  It  is  not  yet  clear  from  functional 
studies whether the majority of these expanded, activated T 
cells  are  specific  for EBV  antigens  or  alternatively result 
from nonspecific, antigen-independent "bystander" activa- 
tion (6, 7).  Only a limited number of studies have investi- 
gated the diversity of the expanded IM T  cell repertoire; 
two  studies  have  demonstrated selectively amplified sub- 
populations  of CD8 +  T  cells  of undetermined  antigenic 
specificity in the  peripheral blood of acutely infected IM 
patients  (8,  9),  while  another  has  found no  evidence  of 
dominant T  cell expansions  (10).  Although the biological 
significance  of these  repertoire  differences  is  unknown, 
they may reflect the variable clinical manifestations of the 
disease,  ranging from mild symptomatic seroconversion to 
development of severe acute or chronic IM. 
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oq3 TCR  heterodimer with specificity for peptide  antigen 
presented by class I MHC  molecules.  The potential diver- 
sity of the T  cell repertoire is enormous, generated through 
recombination of variable  (TCILAV and TCRBV),  diver- 
sity (TCRBD), and joining (TCRAJ and TCRBJ) gene el- 
ements  during  T  cell  ontogeny.  Diversity  is  further  en- 
hanced  by  the  imperfect  joining  of  the  receptor  gene 
segments and by the addition of non-germline-encoded N 
region nucleotides to the coding ends of the V-(D)-J junc- 
tional regions (reviewed in reference  11). Molecular mod- 
eling of the TCIL predicts that complementarity determin- 
ing regions CD1L1  and CD1L2, encoded by TCRAV  and 
TCRBV gene elements,  interact with the MHC  molecule 
while the hypervariable CDtL3, spanning the V-(D)-J junc- 
tional regions, directly contacts the bound peptide  (12). Al- 
though a broadly selected antigen-specific TCR  repertoire 
may be of advantage to the host, several factors are thought 
to limit the diversity of the  expressed repertoire  for a par- 
ticular  epitope.  These  include  positive  and  negative  thy- 
mocyte selection,  as well as  structural  constraints  imposed 
by a  given peptlde/MHC  combination  (13).  Lymphocyte 
competition  with  successive  antigen  encounters  may also 
lead to selection ofoligoclonal repertoires within the mem- 
ory T  cell pool.  While  a  number  of studies  have investi- 
gated the TCIL usage of CTLs specific for a variety of for- 
eign antigens, only a limited number of studies have directly 
monitored  the  antigen-specific  TCtL  repertoire  develop- 
ment of memory T  cells  (14-16).  In one such study, a fo- 
cusing  of specific  TCIL  clonotypes  selected  during  the 
course of an immune response was shown, providing sup- 
port for preferential restimulation in shaping the peripheral 
antigen-specific T  cell repertoire  (14).  In contrast,  another 
study has shown no major change in repertoire selection in 
the  primary  and  memory  T  cell  responses  (16).  Despite 
these  developments,  much remains  to be learned  about  T 
cell  specificity  selection  and  progressive  evolution  within 
the long-term memory T  cell compartment. 
We  have  recently  reported  that  despite  an  enormous 
TCR  repertoire  potential in each individual,  the  CTL re- 
sponse  to  the  immunodominant  HLA-B8-restricted  EBV 
epitope  FLR.GRAYGL consists  of public  TCRs  that  are 
highly  conserved  and  that  reproducibly  emerge  in  the 
EBV-speclfiC  immune  responses  of  different  individuals 
(17,  18).  The  most  restricted  of these  public  responses  is 
found  m  individuals  who  are  HLA-B8  +,  where  a  single 
public TCR  is found to dominate the response in a num- 
ber  of unrelated  donors  (17).  This  TCR  is  known  to  be 
cross-reactive with the alloantigen HLA-B44 (19).  In HLA- 
B8+/B44 ÷ individuals,  tolerance to this background MHC 
antigen has been shown to diversify the FLRGRAYGL-spe- 
cific TCR repertoire, resulting in the development of a num- 
ber of alternate types of public TCP,  s (18). A strong genetic 
bias in TCR  gene recombination and preferential selection 
of public TCP,_s in the periphery in response to a persistent 
viral  infection  are  thought  to  be  important  factors in  the 
development  of these  exceptionally reproducible  memory 
TCR. responses. 
In the present report, we have monttored the EBV-spe- 
cific  memory TCP,.-/3  response  during  the  course  of pri- 
mary EBV infection in an HLA-B8  + individual with acute 
IM.  This  was  achieved  by  determining  the  TCR-J3  se- 
quences of CTLs specific for the EBNA-3-encoded epitopes 
FLR.GRAYGL or QAKWRLQTL  after  their  isolation  at 
various times after primary infection.  The results show se- 
lection of TCR-[3 diversity within  the  T  cells  responding 
to single viral epitope determinants,  with evidence of anti- 
gen-drlven  clonal  expansions  and  long-term  maintenance 
of a multiclonal  effector response  selected  early in the  In- 
fection. Furthermore, a public TCI<-/3 chain was identified 
in  the  primary  antiviral  response,  and  PCP,  tracking  of 
PBMCs ex vivo showed an expansion  of this chain in the 
peripheral repertoire after clinical diagnosis. 
Materials  and Methods 
Cell Donors.  Donor BT (HLA-A1, 31; -BS, 35) was chagnosed 
with acute IM based on clinical symptoms and serology.  PBMCs 
were isolated from hepannized blood by centrifugation  over Flcoll- 
Paque (Pharmacia  Biotech, Melbourne, Australia)  at the time of 
climcal diagnosis (day 1/sample  referred to as BTI) and at different 
times thereafter  (day 36/BTII, day 85/BTIII, and day 196/BTIV). 
Samples BTI and BTII were taken dunng the acute IM stage when 
the patient was IgM  + for EBV viral capsid anngen and IgG- for 
EBNA. Samples BTIII and BTIV were taken during convalescence 
when the patient showed recovery from the disease and IgG EBNA 
antiboches developed.  The HLA-B8  + status of BT was imtially de- 
termined  by FACScan  ® analysis (Becton Dickinson & Co., Syd- 
ney,  Austraha)  of PBMCs  using  an  anti-HLA-B8 mAb  (clone 
59HA-l; One Lambda Inc., Los Angeles, CA), and confirmed by 
serological typing of the donor's PBMCs. The virus infecting BT 
was  identified  as a  type A  EBV isolate  by PCR  analysis using 
type-specific  pnmers  (20). Control PBMCs were  isolated  from 
healthy EBV-seronegatlve donors PP (HLA-A1, 24; -BS, 14) and 
WH (HLA-A1,-;-BS, 57) and seroposmve donorsJP (HLA-A2, 
28; -BS, 62) and BM (HLA-A1, -; -BS, -). 
Establishment and Maintenance of Cell Lines.  Lymphobhstoid cell 
lines (LCLs) were estabhshed from donors BM (HLA-A1, -; -BS, -) 
and DJM (HLA-A24, 29; -B44, 47) by transformation of B cells 
with  exogenous type A  EBV  (WIL and BL74 isolates,  respec- 
tively)  as described  (21). PBMCs were stimulated  with  PHA as 
described  (22). LCLs were routinely maintained in growth me- 
dium consisting  of RPMI 1640 medium, 2 mM glutamine,  100 
IU/ml pemcillin,  100  ~g/ml  streptomycin,  and  10%  (vol/vol) 
heat-inacnvated fetal bovine serum. PHA blasts were maintained 
m  continuous culture for 6--8 wk in growth medium containing 
20 U/ml rIL-2 (23, 24). 
Selection and Synthesis of  Peptides.  Two HLA-B8-restricted CTL 
epitopes,  FLIKGRAYGL and QAKWRLQTL, were selected  to 
monitor the development of the TCIK-J3 repertoire m donor BT 
dunng acute 1M and convalescence.  Both of these  epitopes  are 
found in EBNA-3 in type A, but not in type B, EBV isolates (25). 
Peptides  were purchased from Chiron Mlmotopes  (Melbourne, 
Australia),  &ssolved in DMSO, and diluted in serum-free RPMI 
1640 medium for use in cytotomcity assays. 
Agar Clonin  2 of T Cells.  T  cell  clones  were generated as de- 
scribed  (26), except that PBMCs from the acute IM donor were 
exposed to growth medium containing 20 U/ml rIL-2 after their 
isolation  over  Fxcoll-Paque  to  avoid  apoptosis  of T  cells (27). 
Briefly, ex vivo PBMCs from donor BT were activated by stimu- 
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homozygous individual  BM at a stimulator/responder cell ratio of 
1:20. After 3 d, dispersed cells were seeded in 0.35% agarose (Sea- 
Plaque;  FMC  BioProducts,  Rockland,  ME)  containing RPMI 
1640 medium, 10% FBS, 25% (vol/vol) supernatant from MLA- 
144 cultures (TIB-201; American Type Culture Collection, Rock- 
ville, MD), and 30 U/ml rlL-2. Colonies were harvested  after an 
additional 3 d, and were amplified  in culture with biweekly re- 
stimulation with  rlL-2 and specific  LCLs.  Colonies were  rou- 
tinely phenotyped using mAbs (all from Becton Dickinson) de- 
tecting the  antigens CD4  (clones SK3  and SK4;  anti-human 
Leu-3a,b-FITC), CD8 (clone SK2; anti-human Leu-2b-PE), and 
CD3  (clone  SK7;  anti-human Leu-4 PerCP).  Flow cytometric 
analysis was performed on a FACScan  ® (Becton Dickinson). 
Cytotoxicity Assay.  Colonies from  donor  BT  were  initially 
screened using the rapid visual T  cell-T cell killer assay (28) to 
ldennfy FLRGRAYGL- and QAKWRLQTL-specific CD8 + CTL 
clones. This procedure requires <103 cells per assay. Epitope-spe- 
cific CTL clones were further amplified in culture, and used as ef- 
fectors  against BM and DJM LCLs, and autologous PHA T  cell 
blasts were pulsed with the appropriate  peptide (100 p.g/ml). Tar- 
get cells, with or without peptide, were incubated with 100 p~Ci of 
5JCr at  37°C  for 90  mln, washed twice by cenmfugation, and 
used in standard  4-h 51Cr release assays. The mean spontaneous 
lysls for targets in culture medium was <20%,  the mean maxi- 
mum lysis  in 0.5% SDS was >90% of total uptake, and the varia- 
tion about the mean specific lysls  was <5%. 
mRNA Isolation and cDNA Synthesis.  Poly A + RNA was ex- 
tracted from 1-5 X 106 CTLs or PBMCs using a QuickPrep Mi- 
cro  mRNA purification kit  (Pharmacla  Biotech.).  An antisense 
TCRBC pnmer (C61) was  used  to  generate first-strand  cDNA 
from 0.5-2 b~g poly A + RNA, and this was followed by RNA 
hydrolysis and the removal of excess primer as described  previ- 
ously (17). 
Amplification and  Sequencing of Rearranged TCR  [3  Sequences. 
TCR-~ rearranged sequences were amplified with five sets of 5' 
TCR13V  family-specific  oligonucleotides  (V~1-5.1,  V[35.2-9, 
V]310-14, V[315-19, and V[320-24) and a 3' TCRBC (C]3) con- 
stant  primer.  The  oligonucleotides VI31-20/C]3  and V[321-24 
were synthesized  according to the methods of Panzara et al. (29) 
and  Kalams  et  al.  (15), respectively.  Amplifications  were  per- 
formed in 25-p,1 reaction volumes using 0.5  p,1 cDNA, 10 pmol 
of each  V[3 and C[3 primer, 200  mM dNTPs, 20 mM MgC12, 
1.25 U  of Taq polymerase  (Ampli-Taq), and a GeneAmp PCR 
9600  system  (Perkin-Elmer Cetus  Corp.,  Norwalk,  CT).  The 
PCR conditions consisted  of denaturation at 95°C for 15 s, an- 
nealing at 60°C for 40 s, and extension at 72°C for 40 s for 35 cy- 
cles, followed by a 5-mm final extension at 72 °C. 13-Actin was 
also amplified as a control for cDNA integrity (30). PCR products 
were  excised  from 2.5%  (0.5×  Trls-buffered EDTA)  NuSieve 
GTG  agarose  gels (FMC  BioProducts)  and  purified  using  a 
QIAEX  gel  extraction  kit  (QIAGEN  Inc.,  Chatsworth,  CA). 
Recovered  PCR  products  were  sequenced in both  dlrecnons 
with  a PRISM Ready Reaction DyeDeoxy Terminator Cycle 
Sequencing Kit and a  373A DNA  sequencer (Applied  Biosys- 
tems,  Inc.,  Foster  City,  CA).  In the  event that  nucleotlde se- 
quence analysis of a PCR product revealed  more than one spe- 
cific  sequence,  the  product  was  subsequently hgated  into  the 
pGEM-T vector system  (Promega,  Machson,  WI).  The  nucle- 
otide sequence of six clones was determined for each ligation. 
Semiquantitative PCR Analysis of TCR  V[3 Gene Expression in 
PBMCs.  TCRBV families 3, 4, 5.1, and 6 were amplified using 
a 5' sense V]3 3, 4,  5.1,  and 6 primer in combination with a 3' 
antisense  TCRBC  constant primer (Cb2; 5'-ATTCACCCAC- 
CAGCTCAGCTCCACG-3'), respectively.  Total TCRBC was 
amplified  using a 5' sense TCRBC primer (Cb5'; 5'-CGTGT- 
TCCCACCCGAGGTCGC-3') and  C62. Amplifications  were 
performed in 25-b~1  reaction volumes using 0.5 b~l cDNA, 10 pmol 
of each V[3 and C[3 primer, 200 mM dNTPs, 20 mM MgC12, and 
1.25 U Taq polymerase.  For sermquantification  of V[3 expression, 
the  exponential phase  of the  PCR  was  determined for  each 
cDNA preparation and primer pair.  The amplification schedule 
was 95°C for 15 s, 60°C for 40 s, and 72°C for 40 s. The ampli- 
fied  products were  resolved  on 2.5%  agarose gels, stained with 
ethidium brormde,  and for some experiments, transferred to nylon 
membranes (Hybond N;  Amersham International, Little  Chal- 
font,  UK),  and  then  hybridized with  a  digoxagenin-ll-dUTP 
(DIG)-labeled TCRBC probe that was detected using the DIG 
luminescent detection  system  according  to  the  protocols  de- 
scnbed by the  manufacturer (Boehnnger Mannheim Australia, 
Castle  Hill,  Australia).  Relative quantification of the  amplified 
products  was  performed  using a  computing densltometer and 
ImageQuant software  version  3.3  (Molecular  Dynamics,  Inc., 
Sunnyvale, CA). The expression of TCRBV families was calculated 
as the percent of total TCR-[3. 
Semiquantitative PCR Analysis of Public FLRGRAYGL-specific 
TCR-[3 Gene Expression in PBMCs.  The pubhc BV6/BJ2S7 FLR- 
GKAYGL-specific rearrangement has  prevlously been  quanti- 
tated by PCR within the TCRBV6 family (17). For analysis of 
the public chain, first-strand  cDNA (200 ng) was used as a tem- 
plate  for PCR  amplificanon using 10 pmol each  of a  5'  sense 
TCRBV6 family-specific primer (V[36) and a 3' antisense TCRBC 
pnmer (Cb2) according to the above-specified PCR  conditions. 
The  amplified  transcripts  were  resolved  on 2%  Nusieve GTG 
agarose  gels, purified,  and 1 pA of this material  (diluted 1/100) 
was used for a second round of PCR using 10 pmol each of VI36 
and  either a  degenerate  primer complementary to  the  CDR3 
region of the  FLRGRAYGL-specific public ]3  chain (~CDR31; 
5'-GTACTGCTC(G,A)TA(A,G,C,T)GC(C,T)TG-3') or  Cb2 
for use as a standard for calculation of the relative  abundance of 
the product obtained with the TCRBV6-~CDR31 primer set. For 
semiquantification of TCRBV expression,  the exponential phase 
of the  PCR  was  determined for  each  cDNA  preparation and 
primer pair. The amplified products were resolved on 2.5% aga- 
rose gels, stained with ethidmm bromide, and quantified densito- 
metrically as described above. 
Results 
Isolation  of FLRGRAYGL-  and  QAKWRLQTL-specific 
CTL  Clones  during  the  Course  of  Primary  EBV  Infection. 
In the present study, two well-defined HLA-B8-restricted 
CTL epltopes, FLRGKAYGL and QAKWRLQTL, were 
selected to monitor the development of the TCR-[3 reper- 
toire  in  donor  BT  during acute  IM  and  convalescence. 
Multiple FLRGRAYGL- and QAKWRLQTL-specific CTL 
colonies were isolated from BT PBMCs at each of the time 
points  (BTI,  BTII,  BTIII,  and  BTIV)  in  a  longitudinal 
study (Table 1). These time points spanned the period from 
acute IM (BTI and BTII), when the donor was IgM  + and 
EBNA  IgG-, to  convalescence (BTIII and BTIV),  when 
the  donor  had  recovered  clinically from  the  disease  and 
EBNA  IgG  antibodies  had  developed.  The  use  of  the 
HLA-B8 homozygous BM LCL provided the essential re- 
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QAKWRLQTL-specific CTL Colonies Generated In Vitro 
from Donor BT during Acute IM and Convalescence 
Proportion of epitope-specific  CD8 + CTL colonies 
screened using the rapid visual T cell-T cell killer assay 
Donor  FLRGRAYGL-specific  QAKWRLQTL-speclfic 
BTI*  7/27  10/27 
BTII  9/66  19/66 
BTIII  9/55  13/55 
BTIV  9/75  10/75 
*IM patient BT was tested on four separate occasions after diagnosis. 
BTI at day 1, BTII at day 36, BTIII at day 85, and BTIV at day 196. 
stimulation population  and also potentiated  the likelihood 
of generating  epitope-specific  CTL  clones  that  were  re- 
stricted through HLA-B8. 
Cytotoxicity data in Fig.  1 a clearly show that the FLR- 
GRAYGL-specific CTL clones isolated at day 1  (BTI) in- 
cluded two clones  (BTI 55  and BTI 64)  that cross-reacted 
with  the alloantigen HLA-B44 on DJM LCL targets,  sug- 
gesting  that  these  clones  expressed  the  public  TCR  rear- 
rangement BV6/BJ2S7  (18).  Three  other  clones  (BTI  17, 
BTI 37, and BTI 45) showed no such cross-reactivity, and 
were categorized putatively as expressing distinct TCR  re- 
arrangements.  As  expected,  the  six  QAKWRLQTL-spe- 
cific  CTL  clones  did  not  cross-react  with  the  DJM  LCL 
targets (Fig.  1 b). Unfortunately, none of the BTI epltope- 
specific clones grew sufficiently well for TCR  analysis.  CTL 
clones  generated  from  subsequent  bleeds,  however,  were 
easier  to  estabhsh  in  culture,  even  though  donor BT was 
still  with  acute  disease  at  the  BTII  bleed  (IgM+;  EBNA 
IgG-). Cytotoxicity profiles of  representative clones that were 
available  for TCR analysis are featured in Fig. 1, c and d. Four 
FLRGRAYGL-specific clones (BTII 180, BTIII 65, BTIV 
13,  and BTIV 58)  cross-reacted with the DJM LCL target 
(Fig.  1 c), and were subsequently shown  (Fig. 2) to express 
the  public  BV6/BJ2S7  rearrangement.  By  contrast,  clone 
BTIII 56  (Fig.  1 c) did not cross-react with the DJM LCL 
target and was shown (Fig. 2) to express a distinct TCR  re- 
arrangement. Every FLRGRAYGL- and QAKWRLQTL- 
specific clone lysed autologous PHA blasts pulsed with the 
exogenous peptide FLRGKAYGL or QAKWRLQTL, re- 
spectively  (Fig.  1,  c and  d),  thus  confirming their  epitope 
specificity initially  designated on the basis of T  cell-T cell 
killing assays. 
Selection of a Public FLR  GRA YGL-reactive I  3  Chain in Pri- 
mary Infection.  We  have  previously  shown  that  a  single 
public  TCR  dominates  the  FLRGRAYGL CTL response 
of a number of healthy, EBV-seropositive  HLA-B8  + indi- 
viduals  (17).  To  confirm  the  cytotoxicity  data  indicating 
selection  of the  public  rearrangement  during  the  primary 
antiviral  response,  the  TCRB  (V-D-J-C)  segments  ex- 
pressed  by  FLRGRAYGL-reactive  CTL  clones  from pa- 
tient BT at day 36  (BTII), still  during the acute  IM stage, 
were  identified  using  TCRBV  family-specific  PCR  fol- 
lowed by direct sequencing (Fig. 2  a).  The TCR-o~ chains 
were  not  determined,  since  in-frame  rearrangements  of 
both ot alleles  have been detected in T  cell clones, whereas 
the  control  of [3  expression  by allelic  exclusion  results  in 
only a  single in-frame  rearrangement  in  each  T  cell  clone 
(34).  Of the  two  clones  available  for TCR  analysis,  BTII 
180  and  BTII  36  both  expressed  a  single  m-frame  BV6/ 
BJ2S7  rearrangement  that was identical  at  the  amino  acid 
level  to  the  public  [3  chain  common  to  other  HLA-B8  + 
donors.  Variation  in  codon usage  within  the  N-D-N  re- 
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Figure  1.  Specific lysls  by 
CTL  clones isolated from  IM 
donor BT during acute IM (BTI 
and  BTI1) and  convalescence 
(BTIII  and  BTI[  9.  CTLs ana- 
lyzed by T cell-T cell kllhng to 
be FLRGRAYGL- (a and c) or 
QAKWRLQTL- (b and d) spe- 
cific  were tested against  BM 
(HLA-A1,  -;  B8,  -)  and  DJM 
(HLA-A24, 29; B44, 47)  LCLs 
and  autologous  PHA-blasts 
pulsed  with  pepnde  FLR- 
GRAYGL (c) or QAKWRLQTL 
(d). E:T ratio =  2:1. Clones iso- 
lated  at  day  1  (BTI), day  36 
(BTII), day 85  (BTII!), and day 
196 (BTII  9  are shown...  BM 
LCL; [q,  DJM  LCL; [~.  BT 
PHA-blasts  +  pepnde; [],  BT 
PHA-blasts. 
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a 
BTII  180 
BTII  36 
TCRBV  FW  CDR3  FW  TCRBJ 
BV6  C  A  S  S  L  G  Q  A  Y  E  Q  Y  F  G  BJ2S7 
tgt  gcc  age  agc  ttg  gga  caa  acc  tac  aaa  caa  tac  ttc  ggg 
BV6  C  A  S  S  L  G  Q  A  Y  E  Q  Y  F  G  BJ2S7 
tgt  gee  age  agc  tta ggt  caa  acc  tac  uau  cau  tac  ttc  ggg 
b 
BTIII  65 
BTIII  56 
BTIII  60 
BV6  C  A  S  S  S  G  Q  A  Y  E  Q  Y  F  G  BJ2S7 
tgt  gcc  agc  agc  tcc  gga  caa  act  tac  aaa  caa  tac  ttc  ggg 
BV5  C  A  S  S  P  M  D  R  P  N  Q  P  Q  H  F  G  BJIS5 
tgt  gcc  age  age  cct  ata  aac  aua  cca  aat  caa  ccc  caa  cat  ttt  ggt 
BVI2  C  A  I  S  A  A  G  E  T  T  E  A  F  F  G  BJISI 
tgt  gcc  atc  agt  gcc  gca  aau  oag  acc  act  aaa  act  ttc  ttt  gga 
C 
BTIV  13 
BTIV  58 
BV6  C  A  S  S  L  G  Q  A  Y  E  Q  Y  F  G  BJ2S7 
tgt  gcc  agc  agc  ttg  gga  caa  acc  tac  aaa  cam  tac  ttc  ggg 
BV6  C  A  S  S  L  G  Q  A  Y  E  Q  Y  F  G  BJ2S7 
tgt  gcc  agc  agc  tta  ggg  cau  acg  tac  aaa  caa  tac  ttc  ggg 
LCI3  BV6  C  A  S  S  L  G  Q  A  Y  E  Q  Y  F  G  BJ2S7 
tgt  gcc  agc  agc  tta  ggg  caa  acc  tac  aaa  caa  tac  ttc  ggg 
Figure 2.  TCI<-[3  junctional region sequences from FLR.GR.AYGL-reactlve  CTL clones isolated at different time points after pnmary EBV refection 
in patient BT. The V-D-J region sequences of clones isolated at (a) day 36/BTII,  (b) day 85/BTIII, and (c) day 196/BTIV after clinical diagnosis are 
shown  A translated amino acid sequence is shown above each corresponding nucleotlde sequence. The actual sequence obtained for each TCR-~ chain 
extended at least 80 nucleotldes further 5' of the sequence shown. For comparison, the TCP,-~ junctional  region of a representative public FLR- 
GRAYGL-speclfiC  clone from an HLA-B8 + donor LC (LC13) is also shown. Designations for TCRBV and TCRBJ  gene elements follow that of 
Arden et al. (31) and Toyonaga et al. (32), respectively For each clone, the deduced amino acid sequence of the CDl<3-eqmvalent loop, defined accord- 
mg to Chothla et al. (33), is shown putatively supported by two frame work branches (FW). TCP,.BJ germhne sequences are underhned and in normal 
print  TCRBD germline sequences are italicized and underlined. A single m-frame TCR-~ rearrangement was detected for each clone, and an out- 
of-frame rearrangement was also detected in BTIII 56. The TCR.-]3 sequences of clones BTII 180, BTII 36, BTIII 65, BTIV 13, and BTIV 58 were re- 
confirmed by independent analyses  starting from new P,.NA lsolanons from each of these clones These sequences are available  from EMBL/GenBank/ 
DDBJ under accession  numbers Z73085-Z73090. 
gions of these clones showed that they were  generated by 
different rearrangement  events,  indicating strong selection 
for this public TCR. component given the potential diver- 
sity ofFLRGRAYGL-specific TCI<-[3 chains (18). 
Development  of  the  FLRGRAYGL-specific  memory 
TCR  response was  monitored longitudinally by sequenc- 
ing the TCRB  genes of the FLRGRAYGL-specific CTLs 
that were isolated at further time points after diagnosis. At 
day 85  (BTIII), a highly homologous public [3 chain, with 
a  single amino acid substitution in the CDR.3  region, was 
identified for clone BTIII 65 (Fig. 2 b). In addition, a num- 
ber of distinct [3 chains were expressed by clones BTIII 56 
and BTIII 60  (Fig. 2  b).  Comparison of these chains with 
previously reported public FLRGRAYGL-specific 13 rear- 
rangements showed no structural homology between these 
chains.  At  day  196  (BTIV),  the  public  [3  response  was 
found  to  persist,  with  clones BTIV  13  and  BTIV  58  ex- 
pressing the  public BV6/BJ2S7  rearrangement  (Fig.  2  c). 
Notably, clones BTIV  13  and BTII  180,  which were  iso- 
lated 160  d  apart, had identical rearrangements, suggesting 
that  they arose by antigen-driven expansion from  a  single 
progenitor clone. Although two other FLRGRAYGL-spe- 
cific CTL lines isolated at day 196 were found to be non- 
clonal since they contained several in-frame  [3  chains,  the 
BV6/BJ2S7  public chain was confirmed by PCR  screening 
not to be present in these lines (data not shown). Overall, a 
polyclonal  memory  CTL  response  containing  a  public 
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TCR-[3  component  was  selected  and  maintained  long- 
term in response to FLRGKAYGL  after a  primary symp- 
tomatic EBV infection in patient BT. 
Selection of TCR-j8 Diversity within tke  QAKWRLQTL 
Response.  TCIK-[3 selection and development in the QAK- 
WRLQTL-specific  memory  response  was  monitored  in 
parallel with  the  FLRGRAYGL  response  in  patient  BT. 
Five distinct [3 chain sequences were identifed for the six 
clones isolated at day 36 (BTII; Fig. 3 a). Despite this over- 
all diversity, three  of the clones  (BTII:  158,  68,  and  141) 
preferentially used the TCRBV  gene BV3,  and five clones 
(BTII:  102,  176,  175,  158,  and  68)  expressed a  common 
TCRBJ  element, BJ2S5.  The CDR3  region, which inter- 
acts  directly with  the  peptide  epitope  (35),  was  also  re- 
stricted in length to 8-11  amino acids in all of the clones. 
Conservation  of a  non-germline-encoded  proline residue 
in  the  hypervariable  CDR3  region  of clones  BTII  102, 
BTII  176, and BTII  175 was also observed. Further, in the 
response at day 85 (BTIII), all the QAKW1KLQTL-specific 
clones  expressed  proline  in  the  second  position  of  the 
CDR3  region (Fig. 3 b), a finding that is likely to reflect se- 
lection by antigen. Several [3 chains identified earlier at day 
36  (BTII:  102,  176,  and  175)  were  found to  recur at this 
later time point in clones BTIII 1, BTIII 13, and BTIII 44. 
These  same  chains,  as  well as  the  BV4/BJ1S2  rearrange- 
ment  of clone BTIII  185,  were  found to reemerge at day 
196  (Fig. 3  c).  Overall, a  diverse QAKWRLQTL-specific CTL  TCRBV  FW  CDR3  FW  TCRBJ 
a 
BTII  102  BY5.1  C  A  S  S  P  E  V  G  E  T  Q  Y  F  G  BJ2S5 
tgc  gcc  agc  agc  ccc  aaa  otg  ggg  aaa  acc  cam  tac  ttc  ggg 
BTII  176  BV5.1  C  A  S  S  P  E  V  G  E  T  Q  ¥  F  G  BJ2S5 
tgc  gcc  agc  age  ccc  aaa  atg  ggg  aaa  acc  caa  tac  tic  ggg 
BTII  175  BV21  C  A  S  S  P  G  S  A  R  S  G  E  T  Q  Y  F  G  BJ2S5 
tgt  gcc  age  agc  ccc  ggc  aac  uca  egg  agt  ggg  aaa  acc  caa  tac  tic  ggg 
BTII  158  BV3  C  A  S  S  L  L  Y  Q  G  G  E  T  Q  Y  F  G  BJ2S5 
tgt  gcc  agc  agt  tta  ctc  tat  cau  uau  aga  aaa  acc  cau  tac  ttc  ggg 
BTII  68  BV3  C  A  S  S  F  L  P  L  R  A  Q  E  T  Q  Y  F  G  BJ2S5 
tgt  gcc  agc  agt  tic  ctc  ccc  cta  cau  acc  caa  oaa  acc  caa  tac  ttc  ggg 
BTII  141  BV3  C  A  S  S  G  S  G  G  A  N  T  E  A  F  F  G  BJIS1 
tgt  gcc  agc  agt  ggc  tcg  ggu  aau uca  aac  act  aaa  act  tic  ttt  gga 
b 
BTIII  1  BV5.1  C  A  S  S  P  E  V  G  E  T  Q  Y  F  G  BJ2S5 
tgc  gCC  agc  agc  ccc  uaa  utg  ggg  uaa  acc  caa  tac  ttc  ggg 
BTIII  13  BV5.I  C  A  S  S  P  E  V  G  E  T  Q  Y  F  G  BJ2S5 
tgc  gcc  agc  agc  ccc  aaa  atg  ggg  uaa  acc  caa  tac  tic  ggg 
BTIII  44  BV21  C  A  S  S  P  G  S  A  R  S  G  E  T  Q  Y  F  G  BJ2S5 
tgt  gcc  agc  agc  ccc  ggc  aac  aca  cgg  agt  ggg  aaa  acc  caa  tac  ttc  ggg 
BTIII  53  BV3  C  A  S  S  P  L  P  G  T  G  A  Y  S  N  Q  P  Q  H  F  G  BJIS5 
tgt  gcc  agc  agt  cca  cta  ccc  uuu  aca  uu~  act  tat  aac  aat  caa  ccc  caa  cat  ttt  ggt 
BTIII  85  BV4  C  S  A  I  P  Q  G  A  A  G  Y  T  F  G  BJIS2 
tgc  agc  gca  arc  cca  cau  aaa  occ  gct  aac  tac  ace  ctc  ggt 
C 
BTIV 32  Bq21  C  A  S  S  P  G  S  A  R  S  G  E  T  Q  Y  F  G  BJ2S5 
tgt  gcc  agc  agc  ccc  ggc  aac  aca  egg  agt  ggg aao  acc  caa  tac  tic  ggg 
BTIV 54  BV5.1  C  A  S  S  P  E  V  G  E  T  Q  Y  F  G  BJ2S5 
tgc  gcc  agc  age  ccc  uaa  atg  ggg  aau  acc  caa  tac  ttc  ggg 
BTIV 47  BV4  C  S  A  I  P  Q  G  A  A  G  Y  T  F  G  BJIS2 
tgc  agc  gca  atc  cca  cau  aGG  aCC  gct  uac  tac  acc  ttc  ggt 
Figure 3.  TCR-[3 juncuonal region sequences from QAKWP-.LQTL-reactlve  CTL clones isolated at different time points after primary EBV lnfectxon 
in patient BT. The V-D-J region sequences of clones Isolated at (a) day 36/BTII,  (b) day 85/BTIII,  and (c) day 196/BTIV after climcal diagnosis are 
shown. The actual sequence obtained for each chain extended at least 80 nucleotIdes further 5' of the sequence shown. A smgle m-frame TCR-[3 rear- 
rangement was detected for each clone  TCRB V, J gene segments, and CDR3 regaon loops are presented and assigned as outlined in the legend of Fig 
2. The conserved CDR3 prohne residue is tnghhghted in bold type. These sequences are available  from EMBL/GenBank/DDBJ  under accession  num- 
bers Z73091-Z73097. 
response was found in patient BT  that showed features of 
antigen-driven selection and  long-term persistence of ex- 
panded populations of distinct CTL clonotypes. 
V~  Families Associated with  FLRGRAYGL  and  QAK- 
WRLQTL Recognition Are  Not  Selectively Expanded  in  the 
PBMC.  Identification of several V[3  families involved m 
the  specific immune  recognition  of EBV  during IM next 
prompted us to determine whether, by selective amplifica- 
tion, any of these gene families represent major expansions 
in  the  peripheral T  cell repertoire  during  the  course  of 
the  disease. Using a  semiquantitative PCR  approach with 
primers specific for TCRBV  families 3,  4,  5.1,  and 6,  the 
relative expressxon of each TCtLBV  gene was  initially as- 
sessed in the healthy EBV-seronegative control donors PP 
and BM,  and a  third EBV-seroposltive donor JP  was  also 
analyzed longitudinally during a 10-mo period (Table 2). This 
approach  established a  normal  range  of relative TCRBV 
expression  and  confirmed  the  validity  of this  technique 
since interindividual variation was  observed and  found  to 
be reproducible between independent analyses. V[3  reper- 
toire  analysis  was  next  performed  on  sequential  PBMC 
samples from donor BT  (Table 2).  The  results showed no 
apparent change in TCRBV  3, 4, 5.1, or 6 expression dur- 
ing the  course  of primary EBV  infection.  In addition, no 
selective perturbation in TCRBV  3, 4, 5.1, or 6 expression 
was  identified when  these  results  were  compared to  the 
normal  control  range  (Table  2).  These  results  imply  that 
relative to the total TCR-[3  repertoire, several V[3 families 
known  to be specifically associated with EB viral recogm- 
tion were not preferentially expanded in response to a pri- 
mary EBV infection in this individual. 
Tracking the Development of a Public FLR  GRA YGL-spedfic 
Chain in PBMCs Ex Vivo.  Having  demonstrated  the  pres- 
ence  of a  pubhc  FLRGRAYGL-reactive compartment  of 
CTL clones from the acute to the convalescent stage of the 
infection,  we  were  interested  in  directly momtorlng  the 
progressive evolution of this T  cell population ex vivo. Us- 
ing a double-step semiquantitative PCR procedure that we 
had developed previously (17), the public [3 rearrangement 
was  tracked relative to TCRBV6  expression in peripheral 
blood preparations BTI,  BTII,  BTIII, and BTIV  (Fig. 4). 
Two  HLA-B8 +  EBV  seronegative  donors,  PP  and  WH, 
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in PBMCs 
Percent of TCR-]3* 
Donors  BV3  BV4  BV5.1  BV6 
Controls 
PP  11  14  16  21 
BM  8  12  11  10 
JP (1/95)*  7  7  7  16 
Jp (10/95)  11  10  7  8 
Jp (11/95)  7  6  8  11 
Normal range  7-11  6-14  7-16  8-21 
IM Donor 
BTI~  9  6  4  7 
BTII  10  10  5  7 
BTIII  10  9  6  11 
BTIV  9  10  7  10 
*PBMCs were analyzed by semlquanntanve  PCR for relanve expres- 
stun of TCRBV3, 4, 5.1, and 6, as described in Materials and Methods. 
Data are expressed as the percent of total TCR-[3. 
*Donor JP was tested on three separate occasmns dunng a 10-mo pe- 
riod. 
~IM donor BT was tested on four separate occasmns after daagnosls: 
BTI at day 1, BTII at day 36, BTIII at day 85, and BTIV at day 196. 
and a  seropositive HLA-B8 +  donor, JP,  were also assessed 
(Fig. 4). The analysis showed that from the time of diagno- 
sis (BTI) to day 36 (BTII) a threefold increase in expression 
of the  public  [3  chain  had  occurred.  This  expansion  was 
also shown  to be stably maintained during days 85  (BTIII) 
and 196  (BTIV). Furthermore, this upregulated level of the 
public [3 chain was found to be similar to that observed in 
the healthy virus carrier JP, who is known to have a public 
FLRGRAYGL-specific CTL component (our unpublished 
observations). The  identity of each  amplified product  was 
confirmed by direct sequencing, which in the case of sam- 
ples BTI,  BTII,  BTIII, BTIV,  and JP  resulted  in  a  single 
clearly readable BV6/BJ2S7  public  sequence.  In  contrast, 
the  low  abundant  products  obtained  in  samples  PP  and 
WH  were shown  to be mixed and unreadable m  sequence 
(data not shown). These data indicate that the public mem- 
ory CTL  component  of the  FLRGRAYGL  response  was 
expanded during the early immune reaction to EBV infec- 
tion  and  subsequently  maintained  at  stable  levels  during 
convalescence. 
Discussion 
In this first analysis of EBV-specific TCR  selection and 
development in a natural primary infection, several impor- 
tant  findings  have  been  made  concerning  the  specificity, 
emergence,  diversity, and  longevity of the  T  lymphocyte 
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EBV-  IM  EBV+ 
donor  donor BT  donor 
lkb  WH  PP  I  II  III  IV  JP 
a  t 
~,~  .!~'  ,  .  .],  PUBLIC 
BV61BJ2S7 
~1~ i  =  ~  ~-  TOTAL BV6 
Figure 4.  Semlquanntatlve detection  of the pubhc TCR-~  chain m 
PBMC ex VlVO. Semlquantltanve PCR amplificatmn of (a) pubhc BV6/ 
BJ2S7 TCR-~  sequences and  (b)  total TCRBV6  sequences from two 
EBV-seronegative donors (PP and  WH), the IM donor BT at &fferent 
umes after chagnosls  (BTl/day 1; BTII/day 36, BTIIl/day 85; BTIV/day 
196), and the EBV-seroposlnve donor JP. - denotes control reacuons ex- 
cluding template. 
clonotypes comprising the memory CTL response.  First, a 
component  of the primary virus-specific CTL  response m 
IM  was  shown  to  be  specific for  two  antigenic  determi- 
nants,  FLRGRAYGL  and  QAKWRLQTL,  that  are  en- 
coded  within  the  latent  viral  antigen  EBNA-3.  Second, 
TCR-[3 repertoire selection was found to be polyclonal for 
both  these  epitopes,  although  structural  restrictions  on 
recognition  were  documented  that  provide  evidence  for 
antigen-driven selection. Third, longitudinal repertoire anal- 
yses  revealed  that  a  multiclonotypic  CTL  response  was 
maintained during the course of primary infection with the 
reemergence of distinct memory T  cell clonotypes sharing 
similar structural restrictions. 
While  it is well known  that  an  HLA  class  I-restricted, 
virus-specific CTL  component  is activated in  IM  (7,  36), 
the target epitopes of this response have not been identified 
previously.  This  study is,  therefore,  important  in  demon- 
strating that EBNA-3-specific CTL precursors can be iso- 
lated from the peripheral blood during a primary symptomatic 
EBV infection. Interestingly, in healthy virus-immune donors, 
a  hierarchy of epitope immunodominance  has been found 
in which the HLA-B8-restricted EBNA-3 response is typi- 
cally dominated by FLRGRAYGL-reactive CTLs  (25).  Yet 
during primary infection in  donor BT,  the  CTL  response 
to FLRGRAYGL and QAKVCRLQTL was codominant in 
that  specific clones were  reacnvated at  similar frequencies 
after LCL stimulanon in vitro. Although a number of hier- 
archical mechanisms are thought to control epitope immu- 
nogenicity,  including  selective  generation  of peptides  by 
antigen processing, differential binding and competition of 
peptides for  MHC  molecules,  and  TCR  repertoire avail- 
ability (37), the codominance of these responses during the 
acute infectious stage possibly reflects immune  stimulation under conditions of high viral antigen load. Indeed, there is 
an increased prevalence of virus-infected B  cells in the pe- 
ripheral blood of IM donors compared to healthy virus car- 
hers (38,  39).  Recent evidence suggests that these cells ex- 
press the full spectrum of latent viral genes in vivo, and that 
they  disappear from the  circulation  during  convalescence 
(40).  CTLs targeted to latent viral determinants may, there- 
fore, play a crucial role in limiting EBV's colonization  of 
the lymphoid system during acute infection. 
The  availability of an  HLA-B8  +  donor  undergoing  a 
primary symptomatic infection provided us with the unique 
opportunity  to  monitor  antigen-specific  TCR  repertoire 
maturation  from the  acute  to  the  convalescent  stage  of 
the disease.  Of particular interest was the TCR response to 
the EBNA-3-encoded,  HLA-B8-restricted epitope, FLR- 
GRAYGL,  which  is  known  to  be  highly  conserved  in 
healthy virus carriers despite a diverse repertoire of TCRs 
that are capable of reacting with this antigenic determinant 
(18).  To  account  for  this  unprecedented  level  of TCR 
conservation, a model incorporating a strong genetic bias in 
TCR  gene recombination and selective T  cell maturation 
and  expansion  in  the  periphery  in  response  to  persistent 
immune stimulation was proposed (17).  One prediction of 
this hypothesis is that public FLRGRAYGL-specific T  cell 
precursors are likely to be present among the broad range 
of TCR  affinities/avidines that  are stimulated during pri- 
mary infection. In the present study, a number of TCR-[3 
receptor chains other than the public rearrangement were 
identified in the responding IM memory T  cell pool. There 
was, however,  evidence of strong preferential selection of 
the public  chain,  since four out  of five CTL clones  arose 
from independent  T  cell  precursors  that  were  unique  in 
codon  usage  within  the  CDR3  region.  Tracking  public 
TCR-[3  clonotypes  in  the  peripheral  repertoire  ex  vivo 
over the course of the disease also provided evidence that 
shortly after the acute IM phase,  a public  compartment of 
circulating memory T  cells were selectively expanded and 
preserved throughout the recovery phase. These latter find- 
ings are consistent with limiting dilution analyses that have 
shown high levels of EBV-specific memory CTL precur- 
sors  in  healthy  seropositive  donors  that  are  maintained 
throughom tife (41). 
Although  a polyclonal FLRGRAYGL- and  QAKWR- 
LQTL-specific CD8 ÷ effector response was selected in IM, 
restrictions on TCR recognition that appeared to be selec- 
tively maintained in the long-term memory response were 
apparent soon after virus challenge. A multiclonal precursor 
population  of CTLs  expressing  highly  conserved  public 
chains was identifed in the FLRGRAYGL response, while 
the QAKWRLQTL-specific CTLs showed a bias in TCRV 
and J  gene  usage with an amino acid conservation in  the 
CDR3  region.  Both  of these  observations  are  consistent 
with  antigen playing an important role in shaping the  se- 
lected  repetoire.  Moreover,  the  recurrent  clonotypes  of 
each epitope response shared distinct structural restrictions, 
implying their selective preservation over the course of the 
infection.  Similar  structural  patterns  of TCR  restriction 
have previously been reported for viral infections (42,  43). 
Progressive  changes  to  the  primary TCR  repertoire  have 
also been documented in CD4 + helper cells  of mice after 
challenge with antigen in vivo (14), as well as in the natural 
CD8-restricted  immune  response  to  HIV  (44),  where  in 
both  of these  studies,  CDR3  length  restrictions  and  se- 
quence conservation were reported. 
The long-term consequences  of primary infection with 
virus that persists  are unknown in terms of TCR repertoire 
evolution.  Although  in  our  study,  the  TCR-[3  responses 
for  two  separate  antigenic  determinants  remained  poly- 
clonal  up  to  6  mo  after  infection,  showing  no  dramatic 
signs  of  focusing  as  is  known  to  occur  in  the  FLR- 
GRAYGL responses of healthy virus carriers, the competi- 
tion for restimulation between different lymphocytes may 
have been minimal if antigen load and resource availability 
were not limiting at this stage during convalescence. In this 
regard,  clonal  exhaustion  from prolonged overstimulation 
by high doses of antigen (45) may play an important role in 
some of the more extreme complications of IM. 
Preferential expansions of selected TCR-V~ subpopula- 
tions have been demonstrated during the acute phase of in- 
fection  with  simian  immunodeficiency  virus  (SIV)  (46), 
HIV (44),  and EBV (8, 9).  In the case of SIV and HIV, vi- 
rus-specific  cytotoxic  function  has  been  associated  with 
amplified V[3 families, suggestive of a role of these T  cells 
in clearing or limiting the spread of virus in vivo. We used 
a novel approach to analyze the virus-induced TCR reper- 
toire response,  first by determining the  TCR-[3  chains  of 
CTL clones specifically stimulated by viral antigens during 
natural primary infection, and then by monitoring antigen- 
specific TCRBV family expression in the peripheral reper- 
toire ex vivo. This approach avoids several of the problems 
associated with direct repertoire analysis,  namely the pres- 
ence of clonal expansions in memory T  cell populations in 
normal  healthy  individuals  (47,  48),  as  well  as  the  likely 
possibility of TCR-independent,  "bystander" activation of 
memory CTLs induced by the cytokine-rich milieu that is 
produced  during  the  course  of acute  viral infection  (49). 
Based on our analyses,  several V~ families found to be spe- 
cifically associated with EBV recognition in  IM were not 
found to be preferentially expanded in the peripheral rep- 
ertoire  during  the  course of the  disease.  This was  despite 
longitudinal  TCR  sequencing  data,  which  provided  evi- 
dence  of clonal  expansions  of several TCR-[3  clonotypes 
expressing these gene families. Taken together, these find- 
ings  emphasize  the  highly polyclonal nature  of the  TCR 
repertoire responding to EBV in IM. 
A  broadly selected,  epitope-specific  TCR  repertoire  is 
likely to be of advantage to the host against persistent vi- 
ruses  that  use  a variety of mechanisms  to  evade immune 
recognition.  Indeed, it has been suggested that the limited 
TCR repertoire of HIV-1 envelope-specific CTLs may fa- 
cilitate  the  immune  escape of virus variants by restricting 
TCR recognition (15). Epitope loss variants that can escape 
CTL destruction have been identified in natural EBV iso- 
lates (50),  although there appears to be minimal CTL pres- 
1822  T Cell Receptor Selecnon m Infectious Mononucleosis sure  for selection  of these  virus  mutants  (51).  This  lack  of 
pressure  may be  a  consequence  of a  multispecific  antiviral 
T  cell  response,  both  at the level  of CTL  recognition  and 
TCR  specificity  selection.  Overall,  selection  of TCR  di- 
versity  is  likely  to  be  important  in  the  establishment  and 
maintenance of a balanced host-virus coexistence. 
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